ATHE - Shares of Alterity Therapeutics Limited (ATHE) Rise Above Previous 52-Week High
Alterity Therapeutics Limited (NASDAQ:ATHE) traded today at a new 52-week high of $6.12. So far today approximately 132.7 million shares have been exchanged, as compared to an average 30-day volume of 106,000 shares.
In the past 52 weeks, shares of Alterity Therapeutics Limited have traded between the current low of $0.28 and a high of $2.75 and is now at $0.82.
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434).
Alterity Therapeutics Limited (NASDAQ:ATHE) has potential upside of 85.4% based on a current price of $0.82 and analysts' consensus price target of $1.52.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer